Article Text

Download PDFPDF

Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool
  1. Mohammed A Mohammed1,
  2. Rebekah J Moles1,
  3. Sarah N Hilmer2,3,
  4. Lisa Kouladjian O’Donnel2,3,
  5. Timothy F Chen1
  1. 1 Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
  2. 2 Department of Clinical Pharmacology and Aged Care, Royal North Shore Hospital, Kolling Institute of Medical Research, Sydney, New South Wales, Australia
  3. 3 Cognitive Decline Partnership Centre, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Mohammed A Mohammed; mmoh2116{at}uni.sydney.edu.au

Abstract

Objective Medication-related burden (MRB) is a negative experience with medicine, which may impact on psychological, social, physical and financial well-being of an individual. This study describes the development and initial validation of an instrument specifically designed to measure MRB on functioning and well-being—the Medication-Related Burden Quality of Life (MRB-QoL) tool.

Methods An initial pool of 76-items for MRB-QoL was generated. The link to MRB-QoL survey was sent to a sample of consumers living with at least one chronic medical condition and taking ≥3 prescription medicines on a regular basis. Exploratory factor analysis (EFA) was used to determine the underlining factor structure. Internal consistency (Cronbach’s α) and construct validity were examined. The latter was examined through correlation with Medication Regimen Complexity Index (MRCI), Drug Burden Index (DBI) and Charlson’s Comorbidity Index (CCI).

Results 367 consumers completed the survey (51.2% male). EFA resulted in a 31-item, five-factor solution explaining 72% of the total variance. The five subscales were labelled as ‘Routine and Regimen Complexity’ (11 items), ‘Psychological Burden’ (six items), ‘Functional and Role Limitation’ (seven items), ‘Therapeutic Relationship’ (three items) and ‘Social Burden’ (four items). All subscales showed good internal consistency (Cronbach’s α 0.87 to 0.95). Discriminant validity of MRB-QoL was demonstrated via its correlations with MRCI (Spearman’s r −0.16 to 0.08), DBI (r 0.12 to 0.28) and CCI (r −0.23 to −0.15). Correlation between DBI and ‘Functional and Role Limitation’ subscale (r 0.36) indicated some evidence of convergent validity. Patients with polypharmacy, multiple morbidity and DBI >0 had higher median scores of MRB-QoL providing evidence for known group validity.

Conclusions The MRB-QoL V.1 has good construct validity and internal consistency. The MRB-QoL may be a useful humanistic measure for evaluating the impact of pharmaceutical care interventions on patients’ quality of life. Future research is warranted to further examine additional psychometric properties of MRB-QoL V.1 and its utility in patient care.

  • therapeutics
  • general medicine (see internal medicine)

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors MAM contributed to the conception and design, analysis and interpretation, drafted and reviewed the manuscript. RJM contributed to the design and interpretation and reviewed the manuscript. SNH and LKO contributed to the interpretation and reviewed the manuscript. TFC contributed to the conception and design, interpretation and reviewed the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Human Ethics Committee, The University of Sydney (project number: 2016/654).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available. The full version of the MRB-QoL V1 is available from MAM (mmoh2116@uni.sydney.edu.au) and TFC (timothy.chen@sydney.edu.au) on request.